S D Katugampola

Summary

Affiliation: University of Cambridge
Country: UK

Publications

  1. ncbi request reprint Changes in ET(A)-, AT1- and AT2-receptors in the phenotypically transformed intimal smooth muscle layer of human atherosclerotic coronary arteries
    S D Katugampola
    Clinical Pharmacology Unit, University of Cambridge, Addenbrooke s Hospital, UK
    J Cardiovasc Pharmacol 36:S395-6. 2000
  2. pmc [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man
    S D Katugampola
    Clinical Pharmacology Unit, University of Cambridge, Level 6, Centre for Clinical Investigation, Box 110, Addenbrooke s Hospital, Cambridge, CB2 2QQ
    Br J Pharmacol 132:1255-60. 2001
  3. pmc [125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with athersclerosis
    S D Katugampola
    Clinical Pharmacology Unit, University of Cambridge, Level 6, Centre for Clinical Investigation, Box 110, Addenbrooke s Hospital, Cambridge, CB2 2QQ, UK
    Br J Pharmacol 134:143-9. 2001
  4. pmc Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan
    S D Katugampola
    Clinical Pharmacology Unit, University of Cambridge, Level 6, Centre for Clinical Investigation, Box 110, Addenbrooke's Hospital, Cambridge, CB2 2QQ, UK
    Br J Pharmacol 134:1385-92. 2001
  5. ncbi request reprint Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system
    S D Katugampola
    University of Cambridge, Centre for Clinical Investigation, Addenbrooke s Hospital, UK
    Can J Physiol Pharmacol 80:369-74. 2002

Detail Information

Publications5

  1. ncbi request reprint Changes in ET(A)-, AT1- and AT2-receptors in the phenotypically transformed intimal smooth muscle layer of human atherosclerotic coronary arteries
    S D Katugampola
    Clinical Pharmacology Unit, University of Cambridge, Addenbrooke s Hospital, UK
    J Cardiovasc Pharmacol 36:S395-6. 2000
    ..Fewer angiotensin type 2 receptors (AT2) were found in the media of NCA with a significant upregulation of AT2 in both the media and the thickened intima of CAD...
  2. pmc [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man
    S D Katugampola
    Clinical Pharmacology Unit, University of Cambridge, Level 6, Centre for Clinical Investigation, Box 110, Addenbrooke s Hospital, Cambridge, CB2 2QQ
    Br J Pharmacol 132:1255-60. 2001
    ..The maximum response elicited by the peptide was 22.6+/-6% of 100 mM KCl. 6. We provide the first evidence of APJ receptor expression, relative densities and functional properties of (Pyr(1))Apelin-13 in human cardiovascular tissue...
  3. pmc [125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with athersclerosis
    S D Katugampola
    Clinical Pharmacology Unit, University of Cambridge, Level 6, Centre for Clinical Investigation, Box 110, Addenbrooke s Hospital, Cambridge, CB2 2QQ, UK
    Br J Pharmacol 134:143-9. 2001
    ....
  4. pmc Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan
    S D Katugampola
    Clinical Pharmacology Unit, University of Cambridge, Level 6, Centre for Clinical Investigation, Box 110, Addenbrooke's Hospital, Cambridge, CB2 2QQ, UK
    Br J Pharmacol 134:1385-92. 2001
    ....
  5. ncbi request reprint Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system
    S D Katugampola
    University of Cambridge, Centre for Clinical Investigation, Addenbrooke s Hospital, UK
    Can J Physiol Pharmacol 80:369-74. 2002
    ..This study has the advantage of focussing on the actual disease processes, which allow the more precise identification of novel therapeutic targets...